Novavax says its Omicron-specific vaccine candidate works as a booster — and its bivalent shot doesn’t


The findings come within three weeks after Novavax earned two critical green lights from regulators.

Previous Humana prices $1.25B debt offering
Next Meet Pittsburgh's newest Nasdaq company, Coeptis Therapeutics